If idiopathic pulmonary fibrosis (IPF) has affected you, you are not alone. The Esbriet Ambassadors and their families are living with IPF, too. Meet the ambassadors and discover their stories in the biographies below.
All patients represented here are real patients who have personal experience taking Esbriet. Given the progressive nature of IPF, they may not be on Esbriet today. Individual results may vary.
The Esbriet Ambassadors are people who are sharing their life stories and treatment experiences, helping to raise awareness and understanding about IPF and Esbriet.
Esbriet Ambassador
From: New Smyrna Beach, FL
Job: Retired (Nurse Practitioner)
"Knowing there was something I could do to treat IPF made the weight of the diagnosis a little easier to manage.”
Esbriet Ambassador
From: Richmond, VA
Job: Retired (Family Care Practitioner/ Professor)
“I wasn't ready to acknowledge IPF's severity and my need for medication. I had to have been in denial. However, the following year, my test results showed another five percent drop in lung function, so I decided to revisit my treatment options. My doctor and I decided to start Esbriet.”
Esbriet Ambassador
From: Beaver Falls, PA
Job: Retired (School Psychologist)
“My pulmonologist pointed out to us that I'd been diagnosed early. That meant I could start treatment sooner rather than later. He gave me literature about treatments that may slow the progression of IPF. I took them home and my wife and I studied them. My pulmonologist and I agreed that Esbriet might be a good choice for me.”
Esbriet Ambassador
From: Chelsea, MI
Job: Flight Instructor
“Because Esbriet needs to be taken with food, I developed a system for when I eat so that I stick to my dosage protocol. I haven’t had problems with either my liver or my stomach. I’ve always had some sensitivity to the sun. I noticed it was somewhat worse once I started Esbriet. I made sure that I always had sunscreen, especially for my eyelids, and I tried to limit my time outside.”
Esbriet Ambassador
From: Somerset, NJ
Job: Professor of Italian Renaissance History
“I think it’s so important for me to stay on treatment as my doctor recommends. It's all about doing what I can to help slow the decline in my lung function for as long as possible.”
Esbriet Ambassador
From: Sudbury, MA
Job: Retired (General Contractor)
“When I have questions about side effects, I call my doctor’s office. From the beginning, I got on a first-name basis with the nurse practitioner, and she helped me an awful lot. Communication with your healthcare team is very important, so never hesitate to contact them. I always let them know when I need help dealing with a problem.”
Genentech’s educators are called Clinical Education Managers. They do not provide medical advice. If you have questions about your health or treatment, you are encouraged to contact your health care provider.
Genentech’s educators are called Clinical Education Managers. They do not provide medical advice. If you have questions about your health or treatment, you are encouraged to contact your health care provider.
Zitter Health Insights. Policy & Access Tracking Tool for Idiopathic Pulmonary Fibrosis. Published September 2017.
Zitter Health Insights. Policy & Access Tracking Tool for Idiopathic Pulmonary Fibrosis. Published September 2017.
Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only can refer you to a foundation that supports your disease state. We do not endorse or show financial preference for any particular foundation. The foundations we refer you to are not the only ones that might be able to help you.
Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only can refer you to a foundation that supports your disease state. We do not endorse or show financial preference for any particular foundation. The foundations we refer you to are not the only ones that might be able to help you.
The Medicare Extra Help program is not a Genentech program. It is administered by the Social Security Administration. The co-pay amount for Medicare Extra Help changes each year.
The Medicare Extra Help program is not a Genentech program. It is administered by the Social Security Administration. The co-pay amount for Medicare Extra Help changes each year.
This Esbriet $5 Co-pay Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid or any other federal or state government program to pay for their medications are not eligible.
Under the program, the patient will pay a co-pay. After reaching the maximum program benefit, the patient will be responsible for all out-of-pocket expenses.
All participants are responsible for reporting the receipt of all program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. The program is only valid in the United States and U.S. Territories. This program is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. The patient, guardian, prescriber, hospital and any other person using the program agree not to seek reimbursement for all or any part of the benefit received by the patient through the offer of this program. Genentech reserves the right to rescind, revoke or amend the program without notice at any time. Additional terms and conditions apply. Please visit EsbrietCopay.com for the full list of Terms and Conditions.
This Esbriet $5 Co-pay Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid or any other federal or state government program to pay for their medications are not eligible.
Under the program, the patient will pay a co-pay. After reaching the maximum program benefit, the patient will be responsible for all out-of-pocket expenses.
All participants are responsible for reporting the receipt of all program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. The program is only valid in the United States and U.S. Territories. This program is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. The patient, guardian, prescriber, hospital and any other person using the program agree not to seek reimbursement for all or any part of the benefit received by the patient through the offer of this program. Genentech reserves the right to rescind, revoke or amend the program without notice at any time. Additional terms and conditions apply. Please visit EsbrietCopay.com for the full list of Terms and Conditions.
To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including the Esbriet $5 Co-pay Program and support from independent co-pay assistance foundations) and must meet certain financial criteria. Uninsured patients and insured patients without coverage for their medicine must meet different financial criteria.
To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including the Esbriet $5 Co-pay Program and support from independent co-pay assistance foundations) and must meet certain financial criteria. Uninsured patients and insured patients without coverage for their medicine must meet different financial criteria.
Eligible patients will pay as little as $5 per valid prescription, subject to a maximum benefit of $25,000 for a 12-month period.
Eligible patients will pay as little as $5 per valid prescription, subject to a maximum benefit of $25,000 for a 12-month period.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.